The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.

Abstract

Cladribine (2-CdA) is structurally similar to another purine analog, fludarabine (FA), recently accepted in several centers as the first-line treatment in chronic lymphocytic leukemia (CLL). Unfortunately, there is less experience with the use of 2-CdA than with FA in patients with CLL in the majority of Western countries. In the last decade we performed several phase II studies and two phase III randomized trials to evaluate the activity and toxicity of 2-CdA in previously treated and untreated patients with CLL. We have also compared the results of Polish studies with the data presented by other investigators. Similarly to FA this agent has been found to be more effective in previously untreated CLL than in patients refractory to or relapsed after conventional therapy with alkylating agents. In different studies the overall response (OR) rate ranged from 70 to 85% and complete response (CR) from 10 to 47%. Higher CR and OR rates in CLL patients treated with 2-CdA and prednisone than with chlorambucil and prednisone were confirmed in our multicenter, randomized study. Subsequently, we performed a multicenter, randomized study comparing 2-CdA alone with a combination of 2-CdA and cyclophosphamide (CC) or cyclophosphamide and mitoxantrone (CMC). Our updated results seem to indicate that the CC program used as a first-line therapy in CLL gives higher CR and OR and better elimination of minimal residual disease (MRD) than 2-CdA alone. CC is also less myelotoxic than CMC. More recently, we have undertaken a phase II study to determine the efficacy and toxicity of 2-CdA combined with the anti-CD20 monoclonal antibody rituximab in CLL and other refractory or relapsed indolent lymphoproliferative disorders. The preliminary results seem to be better than in similar patients previously treated in our institution with 2-CdA alone. In conclusion, the studies performed in the last decade in Poland and other countries have shown that 2-CdA used alone or in combination with other agents is, similarly to FA, a highly active and relatively safe agent in previously treated and untreated patients with CLL.

• Authors: Tadeusz Robak
• Journal: Annals of hematology (Ann Hematol) Vol. 84 Issue 2 Pg. 63-70 (Feb 2005) ISSN: 0939-5555 [Print] Germany
• PMID: 15558283 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Cladribine

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cladribine (adverse effects, therapeutic use)
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (complications, drug therapy, mortality)
• Neoplasms, Second Primary (etiology)
• Poland
• Randomized Controlled Trials as Topic